This article is more than 5 years old. Information may no longer be current.

Santen Pharmaceutical launches dry eye treatment in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — Santen Pharmaceutical has launched diquafosol tetrasodium ophthalmic solution for treating dry eye in Japan, according to a press release from co-developer Inspire Pharmaceuticals.

Under the terms of a development agreement regarding Diquas (diquafosol tetrasodium ophthalmic solution 3%), Santen will tender Inspire a $1.25 million milestone payment during the fourth quarter. Inspire will be eligible to receive future royalties based on net sales of the compound in Japan, according to the release.

Also under the agreement, Santen may develop and commercialize diquafosol tetrasodium for treating ocular surface disease in Japan, as well as in nine additional countries in Asia.

"We are pleased that Diquas is now available as a new treatment option for dry eye patients in Japan," Adrian Adams, president and CEO of Inspire, said in the release. "We are completing this year with continued strong operational momentum."

Santen is currently sponsoring a phase 3 trial of diquafosol tetrasodium in China.